Replidyne commences Phase I for REP8839
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Replidyne's topical anti-infective candidate REP8839 has begun Phase I studies, the firm says July 18. Replidyne, which recently filed an initial public offering registration statement, submitted an IND for the agent in May (1Pharmaceutical Approvals Monthly July 2006, p. 3)...